Janux Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
JANX007 demonstrates durable responses and manageable safety in MCRPC, with strong PSA reductions and favorable RPFS, especially in taxane-naive and low tumor burden patients. Q2W dosing is preferred, and the program is advancing in both monotherapy and combination settings, targeting earlier lines and PARP inhibitor-refractory populations.
-
Three new programs—PSMA CD28 TRACIr, TROP2 TRACTr, and CD19 ARM—expand a robust pipeline targeting oncology and autoimmune diseases. Strong preclinical and early clinical data support best-in-class potential, with significant market opportunities and a solid financial position to reach key milestones.
Fiscal Year 2024
-
JANX007 interim data show deep, durable PSA responses and a favorable safety profile in advanced prostate cancer, with higher doses yielding better outcomes. The program is advancing to expansion cohorts and combination studies, with strong financial backing and regulatory engagement planned.